Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease

Parkinsonism and Related Disorders

Volumn 20, Issue 12, 2014, Pages 1394-1398

  Bohnen, Nicolaas I ^a,b   Kotagal, Vikas ^a   Müller, Martijn L T M ^a   Koeppe, Robert A ^a   Scott, Peter J H ^a   Albin, Roger L ^a,b,c   Frey, Kirk A ^a   Petrou, Myria ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VAAAHS   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Acetylcholine; Cognitive impairment; Diabetes mellitus; Dopamine; Parkinson disease; PET

Indexed keywords

AGE DISTRIBUTION; AGED; ARTICLE; CHOLINERGIC SYSTEM; COGNITION; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; DENERVATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; EDUCATIONAL STATUS; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; SEX DIFFERENCE; ANALOGS AND DERIVATIVES; COGNITION DISORDERS; COMPLICATION; DIABETES COMPLICATIONS; MIDDLE AGED; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SEVERITY OF ILLNESS INDEX;

BUTYRIC ACID DERIVATIVE; CARBON; DIHYDROTETRABENAZINE; METHYL-4-PIPERIDINYL N-BUTYRATE; PIPERIDINE DERIVATIVE; TETRABENAZINE;

AGED; BUTYRATES; CARBON ISOTOPES; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; TETRABENAZINE;

EID: 84915757039     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.10.008     Document Type: Article

References (35)

1. Tilvis R.S., Kahonen-Vare M.H., Jolkkonen J., Valvanne J., Pitkala K.H., Strandberg T.E. Predictors of cognitive decline and mortality of aged people over a 10-year period. JGerontol A Biol Sci Med Sci 2004, 59(3):268-274.
2. Yaffe K., Falvey C., Hamilton N., Schwartz A.V., Simonsick E.M., Satterfield S., et al. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol 2012, 69(9):1170-1175.
3. Strachan M.W., Reynolds R.M., Frier B.M., Mitchell R.J., Price J.F. The relationship between type 2 diabetes and dementia. Br Med Bull 2008, 88(1):131-146.
4. Luchsinger J.A. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur J Pharmacol 2008, 585(1):119-129.
5. Giuntini M., Baldacci F., Del Prete E., Bonuccelli U., Ceravolo R. Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. Parkinsonism Relat Disord 2014, 20(6):671-672.
6. Klein J.C., Eggers C., Kalbe E., Weisenbach S., Hohmann C., Vollmar S., et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia invivo. Neurology 2010, 74(11):885-892.
7. Aviles-Olmos I., Limousin P., Lees A., Foltynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 2013, 136(Pt 2):374-384.
8. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010, 25(15):2649-2653.
9. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. JNeurol Neurosurg Psychiatry 1992, 55:181-184.
10. Kotagal V., Albin R.L., Muller M.L., Koeppe R.A., Frey K.A., Bohnen N.I. Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord 2013, 19(5):522-526.
11. Aarsland D., Bronnick K., Larsen J.P., Tysnes O.B., Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009, 72(13):1121-1126.
12. Delis D.C., Kramer J.H., Kaplan E., Ober B.A. California verbal learning test manual, adult version 2000, The Psychological Corporation, San Antonio. 2nd ed.
13. Wechsler D. WAIS III technical manual 1997, The Psychological Corporation, San Antonio, TX.
14. Delis D.C., Kaplan E., Kramer J.H. Delis-Kaplan executive function system (D-KEFS): examiner's manual 2001, The Psychological Corporation, San Antonio, TX.
15. Stroop J.R. Studies of interference in serial verbal reactions. JExp Psychol 1935, 18:643-662.
16. Benton A.L., Varney N.R., Hamsher K. Judgment of line orientation, form V 1975, University of Iowa Hopsitals, Iowa City.
17. McDonald W.M., Holtzheimer P.E., Haber M., Vitek J.L., McWhorter K., Delong M. Validity of the 30-item geriatric depression scale in patients with Parkinson's disease. Mov Disord 2006, 21(10):1618-1622.
18. Bohnen N.I., Mueller M.L.T.M., Kotagal V., Koeppe R.A., Kilbourn M.R., Gilman S., et al. Heterogeneity of cholinergic denervation in Parkinson disease. JCereb Blood Flow Metab 2012, 32(8):1609-1617.
19. Shao X., Hoareau R., Hockley B.G., Tluczek L.J., Henderson B.D., Padgett H.C., et al. Highlighting the versatility of the Tracerlab synthesis modules. Part 1: fully automated production of [F] labelled radiopharmaceuticals using a Tracerlab FX(FN). JLabel Comp Radiopharm 2011, 54(6):292-307.
20. 11C] dihydrotetrabenazine. JCereb Blood Flow Metab 1999, 19(12):1376-1384.
21. 15 water PET. Quantification of brain function to tracer kinetics and image analysis in brain PET 1993, 409-418. Excerpta Medica, Tokyo. K. Uemura, N.A. Lassen, T. Jones, I. Kanno (Eds.).
22. Brown C.A., Karimi M.K., Tian L., Flores H., Su Y., Tabbal S.D., et al. Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques. Ann Neurol 2013, 74(4):602-610.
23. 11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. JCereb Blood Flow Metab 2001, 21(11):1354-1366.
24. Shute C.C., Lewis P.R. Electron microscopy of cholinergic terminals and acetylcholinesterase-containing neurones in the hippocampal formation of the rat. ZZellforsch Mikrosk Anat 1966, 69:334-343.
25. Selden N.R., Gitelman D.R., Salamon-Murayama N., Parrish T.B., Mesulam M.M. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998, 121:2249-2257.
26. Monette M.C., Baird A., Jackson D.L. Ameta-analysis of cognitive functioning in nondemented adults with type 2 diabetes mellitus. Can J Diabetes 2014, http://dx.doi.org/10.1016/j.jcjd.2014.01.014.
27. Hedden T., Mormino E.C., Amariglio R.E., Younger A.P., Schultz A.P., Becker J.A., et al. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. JNeurosci 2012, 32(46):16233-16242.
28. Falvey C.M., Rosano C., Simonsick E.M., Harris T., Strotmeyer E.S., Satterfield S., et al. Macro- and microstructural magnetic resonance imaging indices associated with diabetes among community-dwelling older adults. Diabetes Care 2013, 36(3):677-682.
29. Bosco D., Fava A., Plastino M., Montalcini T., Pujia A. Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. JCell Mol Med 2011, 15(9):1807-1821.
30. Rivera E.J., Goldin A., Fulmer N., Tavares R., Wands J.R., de la Monte S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. JAlzheimers Dis 2005, 8(3):247-268.
31. Umegaki H. Neurodegeneration in diabetes mellitus. Adv Exp Med Biol 2012, 724:258-265.
32. Jones J.D., Malaty I., Price C.C., Okun M.S., Bowers D. Health comorbidities and cognition in 1948 patients with idiopathic Parkinson's disease. Park Relat Disord 2012, 18(10):1073-1078.
33. Williams-Gray C.H., Mason S.L., Evans J.R., Foltynie T., Brayne C., Robbins T.W., et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. JNeurol Neurosurg Psychiatry 2013, 84(11):1258-1264.
34. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012, 69(1):29-38.
35. Launer L.J., Miller M.E., Williamson J.D., Lazar R.M., Gerstein H.C., Murray A.M., et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 2011, 10(11):969-977.